Germline Mutation in \textit{RNASEL} Predicts Increased Risk of Head and Neck, Uterine Cervix and Breast Cancer

Bo Eskerod Madsen\textsuperscript{2}, Eliana Marisa Ramos\textsuperscript{1}, Mathieu Boulard\textsuperscript{1}, Katarzyna Duda\textsuperscript{1}, Jens Overgaard\textsuperscript{3}, Marianne Nordmark\textsuperscript{3}, Carsten Wiuf\textsuperscript{2}, Lise Lotte Hansen\textsuperscript{1*}

\textsuperscript{1}Institute of Human Genetics, University of Aarhus, Aarhus, Denmark, \textsuperscript{2}Bioinformatics Research Center (BiRC), University of Aarhus, Aarhus, Denmark, \textsuperscript{3}Department of Experimental Clinical Oncology, University Hospital of Aarhus, Aarhus, Denmark

Abstract

The Background: Ribonuclease L (\textit{RNASEL}), encoding the 2'-5'-oligoadenylate (2-5A)-dependent RNase L, is a key enzyme in the interferon induced antiviral and anti-proliferative pathway. Mutations in \textit{RNASEL} segregate with the disease in prostate cancer families and specific genotypes are associated with an increased risk of prostate cancer. Infection by human papillomavirus (HPV) is the major risk factor for uterine cervix cancer and for a subset of head and neck squamous cell carcinomas (HNSCC). HPV, Epstein Barr virus (EBV) and sequences from mouse mammary tumor virus (MMTV) have been detected in breast tumors, and the presence of integrated SV40 T/t antigen in breast carcinomas correlates with an aggressive phenotype and poor prognosis. A genetic predisposition could explain why some viral infections persist and induce cancer, while others disappear spontaneously. This points at \textit{RNASEL} as a strong susceptibility gene.

Methodology/Principal Findings: To evaluate the implication of an abnormal activity of RNase L in the onset and development of viral induced cancers, the study was initiated by searching for germline mutations in patients diagnosed with uterine cervix cancer. The rationale behind is that close to 100% of the cervix cancer patients have a persistent HPV infection, and if a defective RNase L were responsible for the lack of ability to clear the HPV infection, we would expect to find a wide spectrum of mutations in these patients, leading to a decreased RNase L activity. The HPV genotype was established in tumor DNA from 42 patients diagnosed with carcinoma of the uterine cervix and somatic tissue from these patients was analyzed for mutations by direct sequencing of all coding and regulatory regions of \textit{RNASEL}. Fifteen mutations, including still uncharacterized, were identified. The genotype frequencies of selected single nucleotide polymorphisms (SNPs) established in the cervix cancer patients were compared between 382 patients with head and neck squamous cell carcinomas (HNSCC), 199 patients with primary unilateral breast cancer and 502 healthy Danish control individuals. We found that the genotype frequencies of only one of the 15 mutations, the yet uncharacterized 5'UTR mutation rs3738579 differed significantly between cancer patients and control individuals (P-value: $4.43 \times 10^{-5}$).

Conclusion/Significance: In conclusion, we have discovered an increased risk, a heterozygous advantage and thereby a protective effect linked to the \textit{RNASEL} SNP rs3738579. This effect is found for patients diagnosed with carcinoma of the uterine cervix, HNSCC, and breast cancer thus pointing at \textit{RNASEL} as a general marker for cancer risk and not restricted to familial prostate cancer.

Citation: Madsen BE, Ramos EM, Boulard M, Duda K, Overgaard J, et al. (2008) Germline Mutation in \textit{RNASEL} Predicts Increased Risk of Head and Neck, Uterine Cervix and Breast Cancer. PLoS ONE 3(6): e2492. doi:10.1371/journal.pone.0002492

Editor: Michael Nicholas Weedon, Peninsula Medical School, United Kingdom

Received May 5, 2008; Accepted May 20, 2008; Published June 25, 2008

Copyright: © 2008 Madsen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Financial support was provided by The Danish Cancer Research Foundation, The Danish Medical Research Council, The Novo Nordic, The John and Birthe Meyer, The Bøje Benzon, The Aarhus University Research and The A.P. Møller and Wife Foundations and Frits, Georg and Marie Cecilie Gluds grant. The Danish Cancer Society supported C.W.

Competing Interests: The authors have declared that no competing interests exist.

E-mail: Lotte@humgen.au.dk

Introduction

Ribonuclease L (\textit{RNASEL}) encoding the versatile endoribonuclease RNase L is a key enzyme in the interferon induced antiviral and anti-proliferative pathway, involved in cellular viral defense, single-stranded RNA cleavage and tumor suppressor activities as stress mediated apoptosis, cell proliferation and regulation of protein synthesis [1–5].

RNase L is activated in response to viral infection and the presence of virally encoded dsRNA mobilizes the type I interferons (IFN), which activate a family of 2'-5' oligoadenylate synthetases (OAS) [6,7]. With ATP as substrate these enzymes produce 5'-phosphorylated 2'-5' linked oligoadenylates (2-5A), which activate RNase L by binding to the ankyrin repeats and inducing dimerization, essential for the endonuclease activity of RNase L [8].

Human RNase L comprises 741 amino acids, and three different domains, a nine ankyrin repeat in the N-terminal, a kinase-like and an RNase domain in the C-terminal part. The ankyrin repeats are known to be involved in protein/protein interactions, but the RNase L ankyrin repeats (2 to 4) bind the 2-5A molecule, which initiates the conformational change of RNase L leading to dimerization and thereby activation of the enzyme [9,10]. Based upon sequence comparison it is predicted that...
RNase L should have protein kinase activity, but it has not been experimentally verified [11]. However, two missense mutations (R462Q and K392R) located in the protein kinase region have been shown to affect the enzyme dimerization and activity [12]. R462Q is a frequent and well-characterized mutation and homozygosity for the rare allele reduces the activity of RNase L by 3-fold [13]. K392R, located in the protein kinase-like region II and implicated in binding of ATP in kinases, prevents the dimerization of RNase L and thereby the activation of the enzyme [12]. The kinase-like and ribonuclease domains are related to those found in IRE1, a transmembrane serine/threonine protein kinase receptor involved in the response to unfolded proteins in the ER [14].

RNAEL is located within the hereditary prostate cancer 1 (HPC1) region at 1q25.3. Chromosomal gain comprising this region has been found as a frequent event in uterine cervix cancer [15] and HNSCC [16] and amplification of the entire chromosome arm 1q is considered an early event in breast carcinogenesis [17].

Germline mutations in RNAEL segregate with the disease in prostate cancer families with linkage to the HPC1 region at 1q25.3 [18]. The majority of missense mutations are found within exon 2 encoding the ankyrin repeats and part of the kinase-like domain. Cells from carriers of M1I and E265X showed half the normal activity of RNase L and the normal allele was lost in tumor cells from patients heterozygous for these mutations [18]. E265X terminates translation within the 2-5A binding domain of RNase L, a similar mutation has been shown to eliminate 2-5A binding in mice [1]. The mutation was originally identified in four brothers, three of which suffered from aggressive prostate cancer [18]. Carriers of E265X develop prostate cancer on an average of 11 years before non-carriers from the same families [19]. A founder mutation 471delAAAG, resulting in a truncated protein, is associated with prostate cancer in Ashkenazi Jews [20]. A number of missense mutations are found in hereditary prostate cancer (HPC) families as: G59S, I97L, I220V, S406F, R462Q, Y529C and D541E, no mis- or nonsense mutations have been found in the ribonuclease domain. The mutations G59S, I97L, I220V, G296V, S322F, Y529C and D541E showed normal level of RNase L when measured in a mouse RNase L-/- cell line [3].

Due to the tumor suppressor activities of RNAEL it is suggested that RNase L directly or indirectly suppress one or more steps in the prostate tumorigenesis or metastasis formation [21]. Germline mutations in RNAEL have been intensively studied in sporadic and familial prostate cancer but the results are contradictory. Recently, a comprehensive meta-analysis comprising the mutations D541E, R462Q and E265X concluded that the genotype E541 increased the risk of developing prostate cancer for Caucasian men, regardless of a family history of the disease [21]. In contrast, E541 was found to increase the risk of prostate cancer in Japanese families with multiple affected members [22]. A marginal effect has been seen for E541 in the Swedish population but studies on other populations could not confirm these results [13,19,23,24].

R462Q is located in the kinase-like domain, and the R462Q variant is capable of binding 2-5A, with a reduced ability to dimerize, a configuration necessary for the enzymatic activity [3]. The catalytic activity of the mutant enzyme is decreased three-fold when compared to the wild type RNase L, and it is no longer capable of inducing apoptosis [13]. Males heterozygous for R462Q have a 1.5-fold elevated risk, and homozygous men double the risk of developing prostate cancer, suggesting R462Q to be a predictive marker for the malignancy [13].

Association between the R462Q carriers and risk of developing prostate cancer seems to depend highly on ethnicity. Mutations in RNAEL are found at a very low rate in the German and Swedish population, and no significant association was found between R462Q and risk of prostate cancer [23,25]. Homozygosity for 462Q was significantly more frequent in Finnish prostate cancer families than in controls, and in Euro-Americans with a family history of prostate cancer, R462Q was inversely associated with low grade and low stage disease [19,26]. A significant association was found between R462Q and an increased risk of early-stage and low-grade disease in Euro-Americans patients with no family history [26]. In Afro-Americans R462Q was associated with a positive family history and high-grade tumors [26].

Patients with a familial pancreatic cancer, which are homozygous for 462Q, presented a more aggressive disease with a high risk of developing metastasis [27] and the genotype is associated with age of onset of hereditary non-polyposis colon cancer (HNPCC) [28]. No association was found between breast cancer risk and any R462Q genotype [29]. Recently, a strong link was established between impaired RNase L activity and infection by a novel gammaretrovirus [30]. CDNA from prostate cancer patients with different genotypes for R462Q were used to screen an oligonucleotide array containing the most conserved sequences from all known viruses. Forty percent of the patients homozygous for 462Q were found to be infected by the xenotropic murine leukemia virus (XMLV), whereas only 1.5% of patients being heterozygous and homozygous (RR) carried the virus. Cells, homozygous for Q have a decreased RNase L catalytic activity and loose the ability to go into apoptosis, strongly indicating that RNase L plays a role in clearing viral infection.

It is estimated that 80% of all adults will acquire an HPV infection at some point of their life. Worldwide, 500,000 women are diagnosed with cervical cancer and the prevalence of a genital HPV infection is estimated to be 326 million among adult women [31].

HNSCC is the sixth most frequent cancer form with 650,000 new incidents and 350,000 deaths per year worldwide [31]. The major risk factors are tobacco and alcohol consumption, body mass and HPV infection, the latter is especially associated with oropharyngeal cancer [32].

Breast Cancer is the second most frequent cancer in the world and the most common in women with more than 1 million new cases and more than 411,000 deaths per year [33]. The major risk factors are age, early menarche, late age of first pregnancy, late menopause, hormone exposure, and lack of exercise [34,35].

HPV is the major risk factor for uterine cervical cancer [36] and responsible for approximately one fourth of the HNSCC cases [37]. The highest prevalence is found for squamous cell carcinomas (SCC) located at the tonsils, oropharynx, oral and larynx [38]. The HPV strains 16 and 18 are associated with 99.7% of all cervical cancers [39] and HPV-16 with 86.7% of oropharyngeal SSC, 68.2% of oral SSC and 69.2% of laryngeal SSC [37]. HPV-16 and 18 are among the high-risk viruses, encoding the oncoproteins E6 and E7, which are capable of silencing p53 and pRb, respectively. Thereby, they are omitting important cell cycle checkpoints [40,41].

Di Lonardo et al. were the first to identify HPV-16 DNA in breast carcinomas [42]. Worldwide studies show a considerable geographic difference in the prevalence of HPV in breast carcinomas varying from 0–86%, described in [43]. In addition, the mouse mammary tumor virus (MMTV) has been found in breast tumors, and insertion sites in the human genome affects genes, which are part of gene families and pathways involved in breast carcinogenesis [44]. Likewise, Epstein Barr virus (EBV), human herpes virus-8 (HHV-8) and bovine leukemia virus (BLV) have been detected in breast tumors, reviewed in [45].

The majority of viral infections are cleared by the immune system, and a genetic predisposition could explain why the infection persists and induce cancer in some individuals.
The aim of this study was to establish a specific genotype or a combination of genotypes (haplotype) across RNASEL, which could prove to be a marker for the individual risk of acquiring a persistent HPV infection, thereby increasing the risk of developing especially uterine cervix and head and neck cancer. The promoter region and the 5' and 3' UTR were included in the search for new mutations. A yet uncharacterized 5' UTR mutation, being in linkage disequilibrium (LD) with well characterized missense mutations in exon 2, proved to be a statistical strong marker for increased risk and heterozygous protection from all three cancer forms.

Results and Discussion

Mutational spectrum of RNASEL in cervical carcinomas

As viral infection is implicated in close to 100% of all uterine cervix cancer cases, we hypothesized that if a defective RNase L is responsible for the lack of ability to clear a viral infection, patients with cervix cancer would carry a wide spectrum of mutations affecting the activity or expression level of RNase L. Therefore, leukocyte DNA from 42 patients diagnosed with uterine cervix cancer were screened for mutations by direct sequencing of both DNA strands of all coding and regulatory regions of RNASEL. The HPV genotype was established on DNA isolated from each tumor. We identified 15 different mutations: four non-synonymous (I97L, F364L, R462Q and D541E), one nonsense (E265X), one synonymous (K724K) and nine in untranslated regions (Figure 1).

Non-synonymous and nonsense mutations with the exception of F364L, reported here for the first time, have previously been characterized with specific focus on familial and sporadic prostate cancer. F364L is located on the border of the protein kinase-like domain.

Figure 1. The entire coding and flanking intron sequences, the 5' and 3' UTR and the promoter region of RNASEL were analyzed for mutations by direct sequencing of leukocyte DNA from patients with cervix cancer (primers are listed in table 3). The two well-described exonic SNPs (rs627928 and K724K) are not illustrated. Genotype frequencies of the SNPs determined in the controls are given beneath the illustration of each SNP, along with a P-value of the marginal effect of the SNP. The Bonferroni corrected significance level is 0.05/12 = 0.004. The genotype frequencies of the cases in the remaining 3 SNPs are: rs627928–7:20:13 (G/G:G/T:T); A-T In5–26:13:0 (A/A:A/T:T:T) and K724K–37:3:0 (A/A:A/G:G/G). The ideogram color code is defined as: white, coding region; grey, UTR; black, intragenic regions.

doi:10.1371/journal.pone.0002492.g001
The implication of the 5' UTR SNP rs3738579 in viral and non-viral induced cancer

The genotype frequencies for each sample of cancer patients (breast and HNSCC) were compared to the controls. A significant difference was seen only for rs3738579 in breast cancer, P-value = 0.0012 and in HNSCC, P-value = 0.0006. We found that the genotype frequencies for rs3738579 were similar in our control population and the HapMap European (CEU) population [31], as opposed to the genotype frequencies in the three similar cancer cohorts (see Table 1). Interestingly, a combination of data from all three cancer forms provided strong statistical evidence for rs3738579 as a cancer marker (P-value: 4.43×10⁻⁹). This finding points to RNASEL as a general marker for cancer risk being not exclusively linked to viral induced cancer forms. In addition, heterozygous individuals were overrepresented in the controls, implying a heterozygote advantage and potential protection against the three cancer forms.

Comparison of genotype frequencies in different cohorts

The genotype frequencies were compared between the cervix cancer patients and the controls using Fisher's exact test (Figure 1). The frequencies of SNP rs3738579 were found to differ most in the two groups (P-value: 0.006), but none of the SNPs showed significant differences. Subsequently, we investigated three SNPs in 199 Danish patients diagnosed with primary unilateral breast cancer and in 302 Danish HNSCC patients. SNP rs3738579 was chosen because it showed the most deviating frequencies; SNP R462Q because it is known to affect the RNase L activity, where the genotypes GA or AA are associated with a decrease in RNase L activity; reduced ability to clear viral infections, linked to familial prostate cancer, and to more advanced disease in pancreatic cancer [13,27]; SNP rs6690434, which is located in the promoter region of RNASEL, covering a potential MyoD binding site, could be of possible regulatory importance. RNase L has been found to regulate MyoD mRNA stability and to be involved in myoblast differentiation [50].

Random samples were sequenced to verify the genotypes, established by the primer extension method, of each SNP (rs3738579, SNP R462Q and rs6690434). In total, samples from all cervix cancer patients, 47% (239/504) controls, 34% (62/185) breast cancer patients and 13% (47/375) HNSCC patients were sequenced to verify the interpretation of the genotypes.

Table 1. Genotype frequencies for SNP rs3738579

| Genotype | Control population | HapMap data | Cervix cancer patients | Breast cancer patients | HNSCC patients |
|----------|--------------------|-------------|------------------------|------------------------|----------------|
| CC       | 45 (0.108)         | 7 (0.117)   | 3 (0.071)              | 34 (0.184)             | 54 (0.144)     |
| CT       | 228 (0.545)        | 33 (0.550)  | 17 (0.405)             | 73 (0.395)             | 153 (0.408)    |
| TT       | 145 (0.347)        | 20 (0.333)  | 22 (0.524)             | 78 (0.422)             | 168 (0.448)    |

The genotype frequencies are given for controls, n = 502, the CEU HapMap population, n = 60 cervix cancer, n = 42 breast cancer, n = 199 and HNSCC, n = 382, respectively, and the proportion of individuals with the genotype is given as percent in brackets. The genotype frequencies of the controls and the HapMap population are similar (P-value: 0.95), and the genotype frequencies of the three cancer populations are similar (P-value for cervix and breast: 0.41; cervix and head and neck: 0.48).

Linkage disequilibrium (LD) across RNASEL

To our knowledge the implication of rs3738579 on activity or expression of RNase L is unknown. The mutation is not located within a uORF (untranslated open reading frame) but may change the conformation of the mRNA. One explanation could be that rs3738579 is in linkage disequilibrium (LD) with a not yet identified mutation in the regulatory regions of RNASEL or a causative mutation in a nearby gene within the same haploblock (see Figure 2). The LD pattern across the sequenced region for the control population was calculated. Two independent LD blocks were found, one in the 3’UTR region and one in the region spanning the promoter region and exon 2. If a causative mutation exists, being in LD with rs3738579, it can only be present upstream from the introns flanking exon 2, since all exons, flanking intron and promoter sequences have been directly sequenced in all 42 cervical cancer patients.

A heterozygous advantage was found in the study linking infection by a novel gammaretrovirus (XMLV) to the R462Q genotypes. Here, 40% of the analyzed prostate cancer patients, being homozygous for the Q allele, and 1.9% of the patients being homozygous for the R allele, were infected by XMLV. None of the analyzed heterozygous patients carried the infection [30]. This mutation is in LD with rs3738579, where the heterozygous

Table 2. Odds Ratio for the SNP rs3738579 in the three cancer samples and in the samples combined, compared to the control population.

| Genotype | Cervix Cancer | Head and Neck Cancer (HNSCC) | Breast Cancer | Total: |
|----------|---------------|------------------------------|---------------|--------|
| CC       | 0.638         | 1.394                        | 1.866         | 1.476  |
| CT       | 0.567         | 0.574                        | 0.543         | 0.564  |
| TT       | 2.071         | 1.528                        | 1.372         | 1.511  |

Table 2 shows odds ratios (ODs) for the three different genotypes of rs3738579; overall the ODs are similar for the three types of cancer.
genotypes of both SNPs are linked as well as homozygosity for the rare and frequent alleles, respectively.

Establishment of the HPV genotype

The HPV genotype was established in DNA isolated from cervical carcinomas using the Linear Array HPV Genotyping Test kit (Roche Diagnostics GmbH, Mannheim, Germany), which allow for detection of 37 different HPV genotypes including 13 from the high-risk group. We found no correlation between HPV strains and rs3738579 genotypes. All cervical tumor samples were infected with HPV16 and in addition 52% with HPV18, in total eleven different HPV strains were identified in the 42 cervix patients (Figure 3). In comparison, HNSCC is a highly heterogeneous disease with predominantly squamous cell carcinomas and only 30% of the study sample was expected to carry an HPV infection. This strengthens the hypothesis presented here that RNase L may be a general marker for cancer risk and not specifically linked to viral induced cancers.

Conclusion

A heterozygote advantage and protective potential of RNASEL have not previously been reported. SNP rs3738579 is located within the 5'UTR region and may be implicated in posttranscriptional regulation or a mediator of an existing low penetrant mutation. One such mutation could be the R462Q located within the same exon. 462Q decreases the activity of RNase L up to three fold and has been intensively studied in large prostate cancer

![Figure 2. Linkage Disequilibrium (LD)-plot of the region containing RNASEL. Each square indicates the level of LD between two SNPs. The color code is defined as: red (high LD), LOD(2 and D<sup>-</sup> = 1; shades of pink/red, LOD(2 and D<sup>-</sup> < 1; blue, LOD<sup>-</sup> < 2 and D<sup>-</sup> = 1; white, LOD<sup>-</sup> < 2 and D<sup>-</sup> < 1. The top of the figure shows the genomic position and the known genes in the region (yellow: exon; grey: UTR; black line: intron) [54]. Note that exon 1 is not shown. The two SNPs within the promoter are illustrated to the far right.

doi:10.1371/journal.pone.0002492.g002](#)

![Figure 3. Distribution of HPV genotypes in cervical carcinomas. Thirty-two uterine cervix tumors were infected by more than one HPV strain and all 42 cases were infected by the high-risk HPV16.

doi:10.1371/journal.pone.0002492.g003](#)
Table 3. Primer sequences for DNA sequencing and SNP genotype assessment

| Polymorphism     | Oligonucleotide name     | Oligonucleotide sequence 5' - 3' |
|------------------|--------------------------|----------------------------------|
| rs7534480        | SNPrs7534480             | GTGTAGTGGCGCATTGCT               |
|                  | RNASELPr                 | GTCTCCAAGGCACAAAGTT              |
|                  | RNASELPrF                | GTATGGGTCGCAAAAGTTG              |
| rs6690434        | SNPrs6690434             | GTAGTGTTGCGAGCTGGA               |
|                  | RNASELPr                 | GTCTCCCAAGGCCAAGATTC             |
|                  | RNASELPrF                | GTATGGGTCGCAAAAGTTG              |
| rs2274509        | SNPrs2274509             | CTGGAGGAAGACAAAGATGC             |
|                  | RNASELPr                 | GTCTCCCAAGGCCAAGATTC             |
|                  | RNASELPrF                | GTATGGGTCGCAAAAGTTG              |
| rs3738579        | SNPT373                | GTTCCAGAGAACTCCCAA               |
|                  | RNASEL2ar2               | CTCTATGCACTGTCGTC                |
|                  | RNASEL2pr2               | GTATCAAGTGTCTTCTCTC              |
| i97L             | SNPI97L                 | GCAATGGCTGGAGAGA                 |
|                  | RNASEL2ar2               | CTCTATGCACTGTCGTC                |
|                  | RNASEL2af                | CTCCATTTACAGGAAAAAGGC             |
| E265X            | SNPE265X                | CTGGAGCAAGAGAGCA                 |
|                  | RNASEL2br                | GAGGGAGAAGAATCTTGTTGGAG           |
|                  | RNASEL2m3                | AGTGGAGAGAAGACAGCTTG              |
| F364L            | SNPF364L                | GTATGGGCAACTCAGTG                |
|                  | RNASEL2c                 | CTCTGAGCTTTCTCCTC                |
|                  | RNASEL2c2                | GATCTCAGGTGCGACAGG               |
| rs486907         | SNPR462Q                | AAATATAGGAGACAGAGACTT            |
|                  | RNASEL2or                | CTCTAGGCTTTCTCCTC                |
|                  | RNASEL2cr2               | CAGTCTGCTGCGGAGCAGG              |
| rs627928         | SNPD541E                | GAAGATCATCTAATTTGGGA             |
|                  | RNASEL4r                 | CACCTTCTCAGTGAGG                 |
|                  | RNASEL                  | CATCTTTCTGGTTGAGATTGAGAG        |
| A4Intron2        | SNPAGln2                | GGATTCTTTTGTGTTAGTTAGG           |
|                  | RNASELIn2r               | GAACCCGATATAATAGGTTAG             |
|                  | RNASELIn2c               | GATCTCAGGTGCGACAGG               |
| rs516134         | SNPrs516134              | GAGAAGGCTGTCTTGCT                |
|                  | rs516134r                | GCACAGATTGTTAAGAGGAC             |
|                  | rs516134f                | GAGGCTCAAATGCTGAGAG             |
| rs533259         | SNPrs533259              | CTGTGACCCTGCACAGCTCT             |
|                  | rs533259r               | CGACTGCTGCACTGAG                 |
|                  | rs533259f               | GAACAGTGCTGAGACTGAG              |
| rs11807829       | SNPK524K                 | CAGCTCCTCACACTGAGGG              |
|                  | RNASEL7c                 | CTCTACGCTAAAGTACTGAGTC           |
|                  | RNASEL7l                 | CAAAGGTGTGCAACTTGTGG             |
| rs12135247       | SNPrs12135247            | GTATAGTTGCTGGCGACTGAG            |
|                  | RNASEL3’UTrR             | TGTACGAAGATGTTGCTATC             |
|                  | RNASEL3’UTrif            | CTGTTGATCTATGCTTAC              |
| A857C, 3’UTR      | SNPrs1048260             | CAGAAAGTCTCAGGAGATTC             |
|                  | RNASEL3’UTrR             | TGTACGAAGATGTTGCTATC             |
|                  | RNASEL3’UTrif            | CTGGTGTATCTATGCTTAC              |

Table 3. cont.

| Polymorphism     | Oligonucleotide name     | Oligonucleotide sequence 5' - 3' |
|------------------|--------------------------|----------------------------------|
| rs11072          | SNPrs11072               | GTCTGCAAGTGGGAAATTT              |
|                  | RNASEL3’UTrR             | TGTACGAAGATGTTGCTATC             |
|                  | RNASEL3’UTrif            | CTGTTGATCTATGCTTAC              |
| rs1048260        | SNPrs1048260             | GGTGTCATTCAAAAGCTCAG             |
|                  | rs1048260r               | CAGAAACTCCTCAGGAGATTC            |
|                  | rs1048260f               | CTGCCATACCCAGCTCTA               |

doi:10.1371/journal.pone.0002492.t003

Materials and Methods

Cervix cancer patients

Pre-treatment buffy coat blood samples, (n = 40) and tumor tissue samples, (n = 42) were collected from patients with newly diagnosed carcinoma of the uterine cervix. Median age was 59 (range 28-84). Twenty-nine women were postmenopausal, 12 premenopausal. Nineteen women were current tobacco smokers and smoking history was not available in five cases. Tumors were FIGO stage IB, n = 4; IIA, n = 1; IIb, n = 20; IIIa, n = 2 and IIIb, n = 15. The majority of tumors were squamous cell carcinoma, n = 37 while one was an adenocarcinoma, one mixed adenoid/neuroendocrine and 3 were adenosquamous carcinoma.

DNA preparation from fresh frozen cervix cancer tissue for HPV analysis

DNA was isolated from 42 fresh frozen tumor tissues according to the manufacturer’s recommendations for the Linear Array HPV Genotyping Test kit (Roche Diagnostics GmbH, Mannheim, Germany). In brief, the tissue was dissolved in 250 μl PBS, 80 μl tissue lysis buffer (AL) and 20 μl Proteinase K, mixed/vortexed briefly and incubated for 60 min at 56°C. 250 μl lysis buffer (AL), containing carrier RNA was added, mixed and incubated at 70°C for 30 min. 300 μl 96% ethanol was added, the solutions were mixed thoroughly and incubated for 5 min at room temperature. The tubes were briefly centrifuged and all liquid transferred to a QIAamp column, the lysate was removed by a vacuum pump, 750 μl elution buffer was added and collected by centrifugation after 2 min incubation at room temperature. The samples can be stored at 2–8°C for 7 days or at 20°C for 8 weeks.

DNA was purified according to standard procedures.

Control population

DNA was extracted from peripheral blood according to a modified salt precipitation method from 502 Danish medical cohorts, but the results are highly contradictory. Linkage to rs3738579 may help explain these diverse results. Interestingly, the implication of a mutated RSAP on viral induced cervical cancer has not been described before, despite the well-documented role of the enzyme in the degradation of viral RNA. Furthermore, characterization of the new 5’UTR mutation rs3738579 in patients with sporadic breast and HNSCC led to the hypothesis that RNase L is a general marker for cancer risk, not restricted to familial prostate cancer.
students of both sexes in their first year at Medical school [52]. The Local Ethical Committee, Aarhus County, Denmark, approved the current study. All individuals were informed and consented both verbally and in writing.

Breast cancer patients

Matching blood and tumor samples were collected from 199 primary breast cancer patients. All patients had primary unilateral breast carcinoma without evidence of disseminated disease, no other malignancies. Complete clinical, histopathological and biological information were available, the cohort is described in [53]. Purification of DNA was carried out using a modified salt precipitation protocol as described in [52].

Head and Neck cancer patients

DNA was derived from fibroblast cultures obtained from 382 consecutive patients with HNSCC treated at the Aarhus University Hospital. The patients were treated with primary radiotherapy according to the protocols and guidelines from the Danish Head and Neck Cancer Group [http://www.dahanca.dk/]. The primary tumor sites were larynx, oropharynx, hypopharynx, nasopharynx and oral cavity.

Ethical approval

The Local Ethical Committee, Aarhus County, Denmark, approved the current study. All patients were informed and consented both verbally and in writing.

Mutation analysis

Both strands of all DNA fragments were sequenced. Primer sequences and PCR conditions are listed in table 3. The initial standard PCR amplification comprised 20 ng DNA, 1 pmol of each primer, 250 μM dNTP (Roche), 1×buffer (supplied with the enzyme) and 0.5 unit Taq polymerase (Roche) in a final volume of 25 μl.

PCR cycle conditions were as follows: 1 cycle of 94°C for 4 min, 35 cycles of 95°C for 35 sec, 59°C for 40 sec, 72°C for 1 min followed by 72°C for 10 min. Products were analyzed by electrophoresis in a 1% agarose gel stained with ethidium bromide. Generation of a single stranded product for sequencing comprised: 2 μl PCR product from above, 5 pmol primer, 6 μl of a 2.5×buffer (supplied with the BigDye kit, ABI, Foster City, CA) and 2 μl Reaction mix (BigDye ver. 2.0 and 1.1; ABI, Foster City, CA) supplied with dH2O to a final volume of 20 μl. Conditions for cycle sequencing were as follows: 1 cycle of 96°C for 4 min, 25 cycles of 96°C for 30 sec, 59°C for 15 sec, 60°C for 4 min. The products were separated by capillary electrophoresis (ABI 3100, Applied Biosystems, Foster City, CA) and evaluated using the software Sequencing analysis® (Applied Biosystems, Foster City, CA).

Single nucleotide polymorphism (SNP) detection

The primer sequences for PCR amplification of the target region containing one or additional SNPs, and for detecting the individual SNP are listed in Table 3.

The PCR amplification comprised: 20 ng DNA, 200 μM dNTP, 0.4 Units Taq polymerase (Ampliqon, Bie and Berntsen, DK), 1×buffer supplied with the enzyme and additional 1.6 mM MgCl2 in a final volume of 15 μl. Depending on the DNA fragment the annealing temperature was ranging between 54–60°C. The genotypes were determined by single nucleotide extension using the SNaPshot® kit following the manufacturers' instructions (Applied Biosystems, Foster City, CA). All products were detected via capillary electrophoresis using the software GeneMapper® (ABI 3100, Biosysm Solutions, Foster City, CA).

HPV detection

The Linear Array HPV Genotyping Test kit (Roche Diagnostics GmbH, Mannheim, Germany) allows for detection of 37 different HPV genotypes including 13 from the high-risk group. The differentiation between HPV genotypes is based upon PCR amplification of the highly polymorphic L1 region followed by hybridization to specific oligonucleotide probes and colorimetric detection. The manufacturers' guidelines were followed.

Statistical methods

A Bonferroni corrected Fisher’s exact test is used for all tests. For cervical cancer 12 tests are for single marker associations, yielding a Bonferroni corrected significance level of 0.05/12 = 0.004, and 66 tests are made for SNP-pair associations yielding a corrected level of 0.05/66 = 0.0008. For breast cancer and HNSCC 3 tests are made for single marker associations, yielding a Bonferroni corrected significance level of 0.05/3 = 0.0167, and 3 tests are made for SNP-pair associations.

Missing data are handled by omitting individuals with missing data in the genotype counts; e.g. all individuals with missing data in either rs3738579 or R462Q are omitted when calculating the genotype frequencies of that specific SNP-pair.

ODs are calculated as $p(1−q)/(1−pq)$ where $p$ is the frequency of one of the three genotypes in the cancer samples (cervix, head and neck, breast, or combined) and $q$ the frequency of the genotype in the control population.

HapMap population

The genotype frequencies for SNP rs3738579 in the European HapMap population are found by using the CEU population in the HapMap genome browser with HapMap data rel21a on NCBI build 35. [51]

Linkage disequilibrium

Linkage disequilibrium (LD) is investigated by the program HaploView (v. 3.31) using genome build NCBI35 [54]. Only polymorphic SNPs are shown in Figure 2.

Acknowledgments

T. Kjeldsen and E.L. Hein are greatly acknowledged for their excellent technical assistance.

Author Contributions

Conceived and designed the experiments: CW LH ER MB KD. Performed the experiments: BM ER MB KD. Analyzed the data: CW BM LH ER MB KD. Contributed reagents/materials/analysis tools: JO LH MN. Wrote the paper: LH. Other: Contributed to the manuscript: CW BM.

References

1. Zhou A, Hassel BA, Silverman RH (1993) Expression cloning of 2-5A-dependent RNasea: a uniquely regulated mediator of interferon action. Cell 72: 753–765.

2. Hassel BA, Zhou A, Sotomayor C, Maran A, Silverman RH (1993) A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO J 12: 3297–3304.

3. Xiang Y, Wang Z, Murakami J, Plummer S, Klein EA, et al. (2003) Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates. Cancer Res 63: 6795–6801.

4. Rusch L, Zhou A, Silverman RH (2000) Caspase-dependent apoptosis by 2',5'-oligoadenylate activation of RNase L is enhanced by IFN-beta. J Interferon Cytokine Res 20: 1091–1100.
27. Bartsch DK, Fendrich V, Slater EP, Sina-Frey M, Rieder H, et al. (2005) Role of protein synthesis with enzyme from interferon-treated cells. Nat 268: 537–540.

26. Hovanessian AG, Brown RE, Kerr IM (1977) Synthesis of low molecular weight inhibitors of protein synthesis and enzyme from interferon-treated cells. Proc Natl Acad Sci U S A 75: 256–260.

25. Nakai S, Paranjape JM, Silverman RH (1998) RNase L limerization in a mammalian two-hybrid system in response to 2',5'-oligoadenylates. Nucleic Acids Res 26: 1522–1527.

24. Dong B, Nica M, Winter P, Silverman RH (2003) Basis for regulated RNA cleavage by functional analysis of RNA L and Ire1p. Rna 7: 361–373.

23. Tanaka N, Nakashima M, Kusakabe Y, Goto Y, Kitade Y, et al. (2004) Structural basis for recognition of 2',5'-linked oligoadenylates by human ribonuclease L. Embo J 23: 3929–3938.

22. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298: 1912–1918.

21. Dong B, Silverman RH (1999) Alternative function of a protein kinase homology domain in 2',5'-oligoadenylate dependent RNase L. Nucleic Acids Res 27: 439–445.

20. Rennert H, Bercovich D, Hubert A, Abeliovich D, Rozovsky U, et al. (2002) A preliminary investigation of genomic screening in cervical carcinoma by comparative genomic hybridization? Br J Cancer 90: 1976–1980.

19. Halder A, Halder S, Fauzdar A (2005) The protein kinase complement of the human genome. Science 298: 1912–1918.

18. Liu CY, Wong HN, Schauerte JA, Kaufman RJ (2002) The protein kinase/endoribonuclease IRE1alpha that signals the unfolded protein response has a luminal N-terminal ligand-independent dimerization domain. J Biol Chem 277: 18346–18356.

17. Hoglund M, Gisselsson D, Hansen GB, Sall T, Mitelman F (2002) Multivariate analysis of chromosomal imbalances in breast cancer delineates cytogenetic pathways and reveal complex relationships among imbalances. Cancer Res 62: 2675–2680.

16. Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, et al. (2002) The protein kinase complement of the human genome. Science 298: 1912–1918.

15. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298: 1912–1918.

14. Liu CY, Wong HN, Schauerte JA, Kaufman RJ (2002) The protein kinase/endoribonuclease IRE1alpha that signals the unfolded protein response has a luminal N-terminal ligand-independent dimerization domain. J Biol Chem 277: 18346–18356.

13. Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, et al. (2002) The protein kinase complement of the human genome. Science 298: 1912–1918.

12. Dong B, Silverman RH (1999) Alternative function of a protein kinase homology domain in 2',5'-oligoadenylate dependent RNase L. Nucleic Acids Res 27: 439–445.

11. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298: 1912–1918.

10. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298: 1912–1918.

9. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298: 1912–1918.

8. Naik S, Paranjape JM, Silverman RH (1998) RNase L limerization in a mammalian two-hybrid system in response to 2',5'-oligoadenylates. Nucleic Acids Res 26: 1522–1527.

7. Kerr IM, Brown RE (1978) pppA2

6. Hovanessian AG, Brown RE, Kerr IM (1977) Synthesis of low molecular weight inhibitors of protein synthesis and enzyme from interferon-treated cells. Proc Natl Acad Sci U S A 75: 256–260.

5. Roy FL, Salehzadeh T, Bishal C, Dougherty JP, Pelz SW (2005) A newly discovered function for RNase L in regulating translation termination. Nat Struct Mol Biol 12: 505–512.

4. Hovanessian AG, Brown RE, Kerr IM (1977) Synthesis of low molecular weight inhibitors of protein synthesis and enzyme from interferon-treated cells. Proc Natl Acad Sci U S A 75: 256–260.

3. Rennert H, Bercovich D, Hubert A, Abeliovich D, Rozovsky U, et al. (2002) A preliminary investigation of genomic screening in cervical carcinoma by comparative genomic hybridization? Br J Cancer 90: 1976–1980.

2. Halder A, Halder S, Fauzdar A (2005) The protein kinase complement of the human genome. Science 298: 1912–1918.

1. Silverman RH (1999) Alternative function of a protein kinase homology domain in 2',5'-oligoadenylate dependent RNase L. Nucleic Acids Res 27: 439–445.